KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Edwards Lifesciences (EW) Research & Development (2016 - 2025)

Edwards Lifesciences (EW) has 17 years of Research & Development data on record, last reported at $267.7 million in Q4 2025.

  • For Q4 2025, Research & Development fell 1.25% year-over-year to $267.7 million; the TTM value through Dec 2025 reached $1.1 billion, up 2.41%, while the annual FY2025 figure was $1.1 billion, 2.49% up from the prior year.
  • Research & Development reached $267.7 million in Q4 2025 per EW's latest filing, down from $280.7 million in the prior quarter.
  • Across five years, Research & Development topped out at $280.7 million in Q3 2025 and bottomed at $130.6 million in Q4 2022.
  • Average Research & Development over 5 years is $241.2 million, with a median of $253.4 million recorded in 2024.
  • Peak YoY movement for Research & Development: fell 1.85% in 2022, then surged 68.28% in 2024.
  • A 5-year view of Research & Development shows it stood at $238.0 million in 2021, then tumbled by 45.13% to $130.6 million in 2022, then rose by 23.35% to $161.1 million in 2023, then soared by 68.28% to $271.1 million in 2024, then decreased by 1.25% to $267.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $267.7 million in Q4 2025, $280.7 million in Q3 2025, and $276.2 million in Q2 2025.